Axcella Therapeutics (AXLA) Reports Q4, Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. LLY
5. TSLA
6. META
7. FICO
8. CART
9. INTC
10. SPCX

Go back to Axcella Therapeutics (AXLA) Reports Q4, Provides Business Update

Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 30, 2023 8:00 AM EDT

Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements Axcella presented at Long COVID forum co-sponsored by BIO and Solve M.E. The Company repositioned its strategy to focus on Long COVID Engaged an investment bank to act as a strategic advisor as we explore a range of strategic alternatives to maximize stakeholder value

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella... More